Single compartment drug delivery
Name
Single compartment.pdf
Size
841.25 KB
Format
Adobe PDF
Checksum (MD5)
ce56deb4843af9fce151cfa0b0ae8924
Author(s)
Cima, Michael J.
Daniel, Karen
Mantzavinou, Aikaterini
Ong, Qunya
Sy, Jay C.
Santini, John
Blankschtein, Daniel
Tanenbaum, Laura Melanie
Lee, Heejin, 1976-
Spencer, Kevin C
Date Issued
May 2014
Journal
Journal of Controlled Release
Publisher
Elsevier
Citation
Cima, Michael J., Heejin Lee, Karen Daniel, Laura M. Tanenbaum, Aikaterini Mantzavinou, Kevin C. Spencer, Qunya Ong, et al. “Single Compartment Drug Delivery.” Journal of Controlled Release 190 (September 2014): 157–71.
Version
Author's final manuscript
Abstract
Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as “privileged,” since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jconrel.2014.04.049
